7 research outputs found
Tierexperimentelle Studie zur Untersuchung von Endothelschäden der Aorta nach Kontrastmittel-Applikation von Ioxitalamat und Iomeprol. Quantitativer Nachweis erhöhter Zellproliferation mittels Autoradiographie
No full textRecommended from our members
The Journal of Cell Culture Models
No full textCollection Description:
While often cells are represented and pictured as discrete biological units, we aim to expand our vision where cells are more realistically considered as building blocks of tissues. By focusing on their interactions with other cell types and biocompatible materials, we can better model the integrated nature and three-dimensional structures that inform cell survival, proliferation, differentiation, and biological function. This approach better allows us to understand the molecular and cellular processes that mediate and affect scarring, wound healing, drug toxicity, and cell development. How do cells choose between these outcomes, and how can different cell types and their interactions with materials direct these processes? Our biologically authentic cell culture models help answer these research questions with the goal of contributing to regenerative medicine applications.
This collection can be viewed as a “Journal of Cell Culture Models”, and contains articles written following the processes and adhering to the conventions of the primary scientific literature. Each work herein was authored by undergraduate students at Worcester Polytechnic Institute (WPI) enrolled in an authentic research laboratory course, and credits the teaching assistant and instructor (as corresponding author).
Generating and disseminating this collection was made possible via the generous support of the WPI Women’s Impact Network (WIN) EmpOwER program.Foreword for Volume I:
This inaugural volume reflects the contributions of the students enrolled in the undergraduate laboratory course BB 3570 Cell Culture Models for Tissue Regeneration at Worcester Polytechnic Institute. The students choose, design, build, and test their models. Subsequently, the students prepare their findings as an open-access journal article. While the research and writing are guided by the instructor and teaching assistant, the students are the scientists conceiving, executing, and disseminating their work. I hope they are as proud of their work as I am!Volume I, 2023 contributors:
Olivia Atkins, Claire Behning, Alexander Boucher, Cleo Caldwell, Katherine Corbin, Lilah Delbou, Binh Diec, John Gabelmann, Kelly Heffernan, Lia Kelly, Samantha Lopez, Grace McCarthy, Jaya Mills, Emma Smith, Yizhe Ma (teaching assistant), Louis Roberts (instructor).Foreword for Volume II:
This volume reflects the contributions of the students enrolled in the undergraduate laboratory course BB 3570 Cell Culture Models for Tissue Regeneration at Worcester Polytechnic Institute. The articles in this volume reflect a theme that emerged during the course- investigating the roles of cellular oxidative stress in injury, healing, and cancer. The students chose this theme as a way to study the models they designed, built, and tested. The student groups’ findings are presented herein as an open-access journal article. While the research and writing are guided by the instructor and teaching assistant, the students are the scientists conceiving, executing, and disseminating their work. We are all proud of their creativity!Volume II, 2024 contributors:*
Sarah Aspinwall, Jamie Baines, Hayden Bovard, Tara Bromfeld, Samuel Levitan, William Miller, Sarah Oliveira, Nicole Rannikko, Theresa Rosato, Isabella Sheeran, Grace Solod, Ren Vitellaro, Miles Williams, Vanesa Lopa (teaching assistant), Shruti Shastry (teaching assistant), and Louis Roberts (instructor).
*We wish to acknowledge the research of three additional students (Trevor Bush, Joceyln Hinchcliffe, and Alana Lue Chee Lip). Their article is not included as it may contribute to a publication or patent.Foreword for Volume III
This volume reflects the contributions of the students enrolled in the undergraduate laboratory course BB 3870 Cell Culture Models Laboratory at Worcester Polytechnic Institute. The articles in this volume reflect a theme that emerged during the course- investigating the roles of cellular oxidative stress in injury, healing, and cancer. The students chose this theme as a way to study the models they designed, built, and tested. The student groups’ findings are presented herein as an open-access journal article. While the research and writing are guided by the instructor and teaching assistant, the students are the scientists conceiving, executing, and disseminating their work. We are all proud of their creativity!
We also acknowledge the faculty and staff at the Biomanufacturing Education and Training Center at Worcester Polytechnic Institute, where the course was offered for the first time. We are grateful for the opportunity to perform experimentation in a state-of-the-art research and training facility.Volume III, 2025 contributors*
Emily Azevedo, Stephanie Brownell, Roey Chen, Victoria Corcoran, Lily Eldridge, Lillian Hanly, Maeve Hess, Mackenzie (Ken) Julien, Hannah Ketelhohn, Divya Kumar, Alaina Lambert, Matthew LaSata, Katelyn Lombardo, Larissa Nogueira Gomes, Madeline Ruley, Olivia Santurri, Shruti Shastry (teaching assistant), Danni Li (teaching assistant) and Louis Roberts (instructor).Foreword for Special Issue
This issue reflects the contributions of students enrolled in the undergraduate laboratory course BB 3870 Cell Culture Models Laboratory at Worcester Polytechnic Institute. The student group’s findings are presented herein as an open-access journal article. While the research and writing are guided by the instructor and teaching assistant, the students are the scientists conceiving, executing, and disseminating their work. We are all proud of their creativity!Special Issue contributors*
Trevor Bush, Jocelyn Hinchcliffe, Alana Lue Chee Lip, Shruti Shastry (teaching assistant), Vanesa Lopa (teaching assistant) and Louis Roberts (instructor)
Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry
No full textThe 2MACE score was specifically developed as a risk-stratification tool in atrial fibrillation (AF) to predict cardiovascular outcomes. We evaluated the predictive ability of the 2MACE score in the GLORIA-AF registry. All eligible patients from phase II/III of the prospective global GLORIA-AF registry were included. Major adverse cardiac events (MACEs) were defined as the composite outcome of stroke, myocardial infarction and cardiovascular death. Cox proportional hazards were used to examine the relationship between the 2MACE score and study outcomes. Predictive capability of the 2MACE score was investigated using receiver-operating characteristic curves. A total of 25,696 patients were included (mean age 71 years, female 44.9%). Over 3 years, 1583 MACEs were recorded. Patients who had MACE were older, with more cardiovascular risk factors and were less likely to be managed using a rhythm-control strategy. The median 2MACE score in the MACE and non-MACE groups were 2 (IQR 1-3) and 1 (IQR 0-2), respectively (p < 0.001). The 2MACE score was positively associated with an increase in the risk of MACE, with a score of ≥ 2 providing the best combination of sensitivity (69.6%) and specificity (51.6%), HR 2.47 (95% CI, 2.21-2.77). The 2MACE score had modest predictive performance for MACE in patients with AF (AUC 0.655 (95% CI, 0.641-0.669)). Our analysis in this prospective global registry demonstrates that the 2MACE score can adequately predict the risk of MACE (defined as myocardial infarction, CV death and stroke) in patients with AF. Clinical trial registration: http://www.clinicaltrials.gov . Unique identifiers: NCT01468701, NCT01671007 and NCT01937377
The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2
No full textBackground GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non–vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients’ baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score ≥2; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701
Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry
No full textAim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007
Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
No full textInternational audienceIn this article, the name of the GLORIA-AF investigator Anastasios Kollias was given incorrectly as Athanasios Kollias in the Acknowledgements. The original article has been corrected
